Evelo Biosciences, Inc. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Operating activities
Net loss
Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation expense
Depreciation expense
Change in fair value of warrant and debt derivative liability
Net accretion of discount on marketable securities
Non-cash interest expense
Non-cash lease expense
Loss on extinguishment of debt
Loss (Gain) on disposal of property and equipment
Net foreign currency losses
Changes in operating assets and liabilities:
Prepaid expenses and other current assets
Accounts payable
Accrued expenses and other current liabilities
Operating lease liabilities
Deferred revenue
Other liabilities
Net cash used in operating activities

Investing activities
Purchase of investments
Proceeds from sales and maturities of investments
Cash acquired in the 2016 acquisition of Epiva
Purchases of property and equipment
Proceeds from the sale of fixed assets
Net cash used in investing activities

Financing activities
Net proceeds from the issuance of common stock upon completion of initial public offering
Deferred issuance costs
Net proceeds from the issuance of convertible preferred stock
Proceeds from issuance of common stock, net of issuance cost
Proceeds from the issuance of common stock under employee stock purchase plan and the exercise of stock options
Proceeds from the issuance of long-term debt, net of issuance costs
Settlement of derivative liability
Repayments of long-term debt
Change in stockholders' payable
Net cash provided by financing activities

Effect of exchange rate changes on cash and cash equivalents
Net decrease in cash, cash equivalents and restricted cash
Cash, cash equivalents and restricted cash – beginning of period
Cash, cash equivalents and restricted cash – end of period
Supplemental disclosure of cash flow information
Cash paid for interest
Cash paid for taxes
Noncash investing and financing activities
Conversion of convertible preferred stock into common stock upon closing of initial public offering
Conversion of convertible preferred stock warrants into common stock warrants
Financing and public offering costs in accounts payable and accrued expenses
Property and equipment additions in accounts payable and accrued expenses
Issuance of debt derivative liability in connection with long-term debt facility
Issuance of warrants in connection with long-term debt facility
Accretion of convertible preferred stock to redemption value
Long-term debt assumed in acquisition of Epiva, net of discount
Net non-cash assets acquired in acquisition of Epiva
Public offering cost in accrued expenses
Issuance of common stock warrants

Comments